GSK Plc is a long-term underperformer among Europe’s Big Pharma stocks. And with key drug patents set to expire and vaccine ...
NEW YORK CITY, NY / ACCESS Newswire / February 21, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law ...
GSK PLC closed 21.63% short of its 52-week high of £18.24, which the company reached on May 16th.
Allworth Financial LP boosted its stake in shares of GSK plc (NYSE:GSK – Free Report) by 175.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange ...
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of GSK plc (NYSE: GSK). Shareholders who purchased shares of GSK during the class period ...
GSK PLC closed 20.87% below its 52-week high of £18.24, which the company reached on May 16th.
GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...
The story has been updated to correct the FDA approval date to Friday, February 14 On Friday, February 14, the FDA approved ...
Cruz announces that investors with losses related to GSK plc. ("GSK" or the "Company") (NYSE: GSK) have opportunity to lead the securities fraud class action lawsuit. IF YOU ARE AN INVESTOR WHO ...
GSK plc (LON:GSK – Get Free Report) insider Emma Walmsley sold 120,653 shares of the firm’s stock in a transaction on Monday, ...
GSK PLC on Thursday said its monoclonal antibody Nucala, also known as mepolizumab, has been accepted for review in China. The London-based pharmaceutical company said the China Medical Products ...
GSK's Penmenvy wins FDA approval to protect against five meningococcal serogroups. The CDC panel will vote on usage ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results